Oncology

The discovery of the genetic drivers of cancer was one of the greatest advancements of the modern era. It paved the way for hematology-oncology to become a leading area for innovation and investment. The field of oncology spearheads areas like precision medicine, adaptive clinical trial design, and breakthrough modalities, including cell therapies and therapeutic vaccines. With breakneck innovation comes complexity as well as urgency to get therapies to patients quickly when time is of the essence.

For over three decades, the Health Advances Oncology practice has worked at the forefront of the industry, assisting clients with strategic decision-making to chart development paths, maximize the value of assets, and achieve favorable deals. With deep technical expertise driven by PhD scientists and long familiarity with clinical practice, Health Advances can assist you with business strategies that lead to success.

Oncology Engagements

External Oncology
Experts in Our Network

MD's and PhDs across
Health Advances and Parexel Oncology
Center of Excellence

Oncology Practice Areas

Cell Therapies

Autologous and allogeneic cells, CAR-T, TCR-T, NK, and adoptive T cell therapies

Learn more about our Cell and Gene Therapy Practice

Precision Medicine

Single assay CDx, panel testing, next-generation sequencing, and functional companion diagnostic testing.

Learn more about our Precision Medicine Practice

Biologics

Targeted, bispecific, and immuno-oncology antibodies, antibody-drug conjugates, and more

Small Molecules

Targeted small molecules, protein degraders, radiopharmaceuticals, and cytotoxic chemotherapies

Vaccines

Medical Devices

Breast Cancers

Gastrointestinal Cancers

Colorectal, Stomach, Esophageal, and Liver Cancer

Genitourinary Cancers

Prostate, Bladder, and Kidney Cancer

Gynecologic Cancers

Cervical, Ovarian, Uterine, Endometrial, and Vaginal Cancers

Head and Neck Cancers

Hematologic Cancers

Lymphoma, Leukemia, Myeloma, and Other Myeloproliferative Neoplasms

Neurologic Cancers

Glioblastoma and Neuroblastoma

Rare Cancers

Sarcoma, Neuroblastoma, Uveal Melanoma, and Rare Genetically Defined Cancers

Skin Cancers

Thoracic Cancers

Oncology Case Studies

Health Advances performed a landscape analysis on allogeneic CAR-T companies to inform a client’s cell therapy portfolio strategy. Our team characterized target opportunities based on the client’s technology, defined target-indication validation requirements, and profiled the competitive landscape across indications and cell therapy modalities. Ultimately, we recommended key investments and guided selection of the first program.

A client sought to understand the revenue opportunity in the US and Europe for a therapy targeting hematologic malignancies, in order to optimize its clinical development plan. Health Advances uncovered the advantages and disadvantages of different development approaches, and their impact on the projected sales opportunity across several indications. The client applied our insights to make critical decisions about the clinical trial strategy for this asset.

An investment bank planned to monetize royalties on an oncology radiopharmaceutical and enlisted Health Advances support. Our team assessed key market dynamics and the drivers and barriers to radiopharmaceutical uptake. We surveyed clinicians on future utilization and developed sales forecasts across geographies. The client applied our findings to inform investment negotiations.

A medical device client sought to understand the impact of alternative data packages on market access. Health Advances executed a robust interview program across numerous stakeholders to understand how different scenarios would impact reimbursement. Our client leveraged the findings to inform key investments to support favorable coverage of the device.

A biotech company with a near-approval therapy for a hematologic malignancy sought to understand biomarker testing turnaround times to determine the value of an accelerated testing protocol. Health Advances surveyed clinicians on current turnaround times and quantified the revenue impact of shortened turnaround times. The client leveraged our insights to justify investment into an accelerated CDx protocol.